Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?

Viruses - 6 Jan 2022

Pabjan Paweł, Brzdęk Michał, Chrapek Magdalena, Dziedzic Kacper, Dobrowolska Krystyna, Paluch Katarzyna, Garbat Anna, Błoniarczyk Piotr, Reczko Katarzyna, Stępień Piotr, Zarębska-Michaluk Dorota

Abstract excerpt

Difficult-to-treat populations with chronic hepatitis C (CHC), in the era of interferon treatment, included patients with liver cirrhosis, kidney impairment, treatment-experienced individuals, and those coinfected with the human immunodeficiency virus. The current study aimed to determine whether, in the era of direct-acting antivirals (DAA), there are still patients that are difficult-to-treat. The study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Coinfection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis B

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Sustained Virologic Response

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 35062302
DOI: 10.3390/v14010096
PMCID: PMC8779728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?PMID 35062302Read ↗

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Semantic proximity Read ↗

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye.Semantic proximity Read ↗

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.Semantic proximity Read ↗

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varicesSemantic proximity Read ↗

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity Read ↗

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.Semantic proximity Read ↗

Management of chronic hepatitis C in 2017.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.